


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9370736/publications.pdf Version: 2024-02-01



li kav He

#	Article	IF	CITATIONS
1	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. Journal of Clinical Investigation, 2018, 128, 4397-4412.	8.2	51
2	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood, 2021, 137, 788-800.	1.4	22
3	Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1336-1339.	2.2	15
4	Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1694-1698.	2.2	14
5	Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas. Blood, 2019, 134, 2073-2073.	1.4	3
6	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 269-269.	1.4	2
7	RNA Interference Screen Implicates TNFAIP3 and FOXO1 in MALT1 Inhibition Resistance. Blood, 2016, 128, 837-837.	1.4	0
8	Abstract LB-303: Substrate-mimetic covalent inhibitor of MALT1 is most effective against CARD11 mutant ABC-DLBCL. , 2017, , .		0
9	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. Blood, 2019, 134, 173-173.	1.4	0